TH‐E‐M100J‐05: Early Assessment of Radiotherapy Efficacy with FLT‐PET Imaging

R. Jeraj, K. Mccall, S. Bentzen, P. Harari, M. Ritter, M. Mehta, Wolfgang A. Tome

Research output: Contribution to journalArticle

Abstract

Purpose: Capability to assess treatment response early could dramatically change the practice of radiation therapy as it is performed today. Our aim was to investigate feasibility of repeat 3′‐Deoxy‐3′‐fluorothymidine ([F‐18]‐FLT) PET/CT imaging as a surrogate for early treatment response. Materials and Methods: Multiple patients with different tumor types — head and neck, lung, esophagus and CNS — underwent either a radical (6 weeks) or palliative (2 weeks) radio‐ or chemoradiotherapy. Each patient was imaged twice with FLT‐PET/CT, a marker of cell proliferation. The baseline FLT‐PET/CT scan was acquired up to a week before the start of radiotherapy or chemoradiotherapy. The follow‐up FLT‐PET/CT scan was acquired in the first half of therapy, typically after one to two‐weeks of radiotherapy. The FLT‐PET image acquisition was dynamic over 90 minutes after the injection of FLT. The CT data between the imaging sessions was co‐registered and the corresponding PET data compared and analyzed. Results: The FLT uptake has proved to be high compared to the normal background activity for all investigated tumor types. The absolute FLT uptake varied significantly for different tumor types, with standardized uptake values (SUV) ranging from less than 1 in CNS tumors to over 10 in head and neck and lung tumors. Detectable change in proliferative activity (>20%) was observed within a week of the initiation of therapy. Significant inter‐ and intra‐patient, and high tumor heterogeneity was observed. Conclusions: FLT‐PET/CT imaging is an extremely powerful tool for early assessment of treatment response for a variety of tumor types. While the absolute FLT uptake varied significantly between different tumor types, the signal to background ratio was high. Early treatment assessment is possible as early as one week after the start of therapy. High inter‐ and intra‐patient tumor response variability offers unprecedented possibilities for treatment adaptation.

Original languageEnglish (US)
Pages (from-to)2650
Number of pages1
JournalMedical Physics
Volume34
Issue number6
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Radiotherapy
Neoplasms
Chemoradiotherapy
Therapeutics
Neck
Head
Lung
Radio
Esophagus
Cell Proliferation
Injections

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

TH‐E‐M100J‐05 : Early Assessment of Radiotherapy Efficacy with FLT‐PET Imaging. / Jeraj, R.; Mccall, K.; Bentzen, S.; Harari, P.; Ritter, M.; Mehta, M.; Tome, Wolfgang A.

In: Medical Physics, Vol. 34, No. 6, 2007, p. 2650.

Research output: Contribution to journalArticle

Jeraj, R, Mccall, K, Bentzen, S, Harari, P, Ritter, M, Mehta, M & Tome, WA 2007, 'TH‐E‐M100J‐05: Early Assessment of Radiotherapy Efficacy with FLT‐PET Imaging', Medical Physics, vol. 34, no. 6, pp. 2650. https://doi.org/10.1118/1.2761758
Jeraj, R. ; Mccall, K. ; Bentzen, S. ; Harari, P. ; Ritter, M. ; Mehta, M. ; Tome, Wolfgang A. / TH‐E‐M100J‐05 : Early Assessment of Radiotherapy Efficacy with FLT‐PET Imaging. In: Medical Physics. 2007 ; Vol. 34, No. 6. pp. 2650.
@article{038ec2b785b045438afd735ea568620b,
title = "TH‐E‐M100J‐05: Early Assessment of Radiotherapy Efficacy with FLT‐PET Imaging",
abstract = "Purpose: Capability to assess treatment response early could dramatically change the practice of radiation therapy as it is performed today. Our aim was to investigate feasibility of repeat 3′‐Deoxy‐3′‐fluorothymidine ([F‐18]‐FLT) PET/CT imaging as a surrogate for early treatment response. Materials and Methods: Multiple patients with different tumor types — head and neck, lung, esophagus and CNS — underwent either a radical (6 weeks) or palliative (2 weeks) radio‐ or chemoradiotherapy. Each patient was imaged twice with FLT‐PET/CT, a marker of cell proliferation. The baseline FLT‐PET/CT scan was acquired up to a week before the start of radiotherapy or chemoradiotherapy. The follow‐up FLT‐PET/CT scan was acquired in the first half of therapy, typically after one to two‐weeks of radiotherapy. The FLT‐PET image acquisition was dynamic over 90 minutes after the injection of FLT. The CT data between the imaging sessions was co‐registered and the corresponding PET data compared and analyzed. Results: The FLT uptake has proved to be high compared to the normal background activity for all investigated tumor types. The absolute FLT uptake varied significantly for different tumor types, with standardized uptake values (SUV) ranging from less than 1 in CNS tumors to over 10 in head and neck and lung tumors. Detectable change in proliferative activity (>20{\%}) was observed within a week of the initiation of therapy. Significant inter‐ and intra‐patient, and high tumor heterogeneity was observed. Conclusions: FLT‐PET/CT imaging is an extremely powerful tool for early assessment of treatment response for a variety of tumor types. While the absolute FLT uptake varied significantly between different tumor types, the signal to background ratio was high. Early treatment assessment is possible as early as one week after the start of therapy. High inter‐ and intra‐patient tumor response variability offers unprecedented possibilities for treatment adaptation.",
author = "R. Jeraj and K. Mccall and S. Bentzen and P. Harari and M. Ritter and M. Mehta and Tome, {Wolfgang A.}",
year = "2007",
doi = "10.1118/1.2761758",
language = "English (US)",
volume = "34",
pages = "2650",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "6",

}

TY - JOUR

T1 - TH‐E‐M100J‐05

T2 - Early Assessment of Radiotherapy Efficacy with FLT‐PET Imaging

AU - Jeraj, R.

AU - Mccall, K.

AU - Bentzen, S.

AU - Harari, P.

AU - Ritter, M.

AU - Mehta, M.

AU - Tome, Wolfgang A.

PY - 2007

Y1 - 2007

N2 - Purpose: Capability to assess treatment response early could dramatically change the practice of radiation therapy as it is performed today. Our aim was to investigate feasibility of repeat 3′‐Deoxy‐3′‐fluorothymidine ([F‐18]‐FLT) PET/CT imaging as a surrogate for early treatment response. Materials and Methods: Multiple patients with different tumor types — head and neck, lung, esophagus and CNS — underwent either a radical (6 weeks) or palliative (2 weeks) radio‐ or chemoradiotherapy. Each patient was imaged twice with FLT‐PET/CT, a marker of cell proliferation. The baseline FLT‐PET/CT scan was acquired up to a week before the start of radiotherapy or chemoradiotherapy. The follow‐up FLT‐PET/CT scan was acquired in the first half of therapy, typically after one to two‐weeks of radiotherapy. The FLT‐PET image acquisition was dynamic over 90 minutes after the injection of FLT. The CT data between the imaging sessions was co‐registered and the corresponding PET data compared and analyzed. Results: The FLT uptake has proved to be high compared to the normal background activity for all investigated tumor types. The absolute FLT uptake varied significantly for different tumor types, with standardized uptake values (SUV) ranging from less than 1 in CNS tumors to over 10 in head and neck and lung tumors. Detectable change in proliferative activity (>20%) was observed within a week of the initiation of therapy. Significant inter‐ and intra‐patient, and high tumor heterogeneity was observed. Conclusions: FLT‐PET/CT imaging is an extremely powerful tool for early assessment of treatment response for a variety of tumor types. While the absolute FLT uptake varied significantly between different tumor types, the signal to background ratio was high. Early treatment assessment is possible as early as one week after the start of therapy. High inter‐ and intra‐patient tumor response variability offers unprecedented possibilities for treatment adaptation.

AB - Purpose: Capability to assess treatment response early could dramatically change the practice of radiation therapy as it is performed today. Our aim was to investigate feasibility of repeat 3′‐Deoxy‐3′‐fluorothymidine ([F‐18]‐FLT) PET/CT imaging as a surrogate for early treatment response. Materials and Methods: Multiple patients with different tumor types — head and neck, lung, esophagus and CNS — underwent either a radical (6 weeks) or palliative (2 weeks) radio‐ or chemoradiotherapy. Each patient was imaged twice with FLT‐PET/CT, a marker of cell proliferation. The baseline FLT‐PET/CT scan was acquired up to a week before the start of radiotherapy or chemoradiotherapy. The follow‐up FLT‐PET/CT scan was acquired in the first half of therapy, typically after one to two‐weeks of radiotherapy. The FLT‐PET image acquisition was dynamic over 90 minutes after the injection of FLT. The CT data between the imaging sessions was co‐registered and the corresponding PET data compared and analyzed. Results: The FLT uptake has proved to be high compared to the normal background activity for all investigated tumor types. The absolute FLT uptake varied significantly for different tumor types, with standardized uptake values (SUV) ranging from less than 1 in CNS tumors to over 10 in head and neck and lung tumors. Detectable change in proliferative activity (>20%) was observed within a week of the initiation of therapy. Significant inter‐ and intra‐patient, and high tumor heterogeneity was observed. Conclusions: FLT‐PET/CT imaging is an extremely powerful tool for early assessment of treatment response for a variety of tumor types. While the absolute FLT uptake varied significantly between different tumor types, the signal to background ratio was high. Early treatment assessment is possible as early as one week after the start of therapy. High inter‐ and intra‐patient tumor response variability offers unprecedented possibilities for treatment adaptation.

UR - http://www.scopus.com/inward/record.url?scp=85024814342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024814342&partnerID=8YFLogxK

U2 - 10.1118/1.2761758

DO - 10.1118/1.2761758

M3 - Article

AN - SCOPUS:85024814342

VL - 34

SP - 2650

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 6

ER -